The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)—A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD),Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)—A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD)
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-07-12 , DOI: 10.1111/apt.18149
Naim Alkhouri ₁ , Deanna McCarthy ₂ , Anne-Cécile V Bayne ₂ , Traci Blonquist ₃ , Karin Yurko-Mauro ₄ , Raj Vuppalanchi ₅ , Eric Lawitz ₆ , Naga Chalasani ₅

Affiliation

We conducted a clinical trial to determine the efficacy of the combination of vitamin E and/or docosahexaenoic acid (DHA) versus placebo in reducing liver fat content after 6 months of intervention in adults with MASLD.

中文翻译：

维生素 E 和二十二碳六烯酸乙酯对代谢功能障碍相关的脂肪肝病 (MASLD) 的影响——一项随机、双盲、安慰剂对照、平行组临床试验 (PUVENAFLD)

我们进行了一项临床试验，以确定维生素 E 和/或二十二碳六烯酸 (DHA) 组合与安慰剂相比，对患有 MASLD 的成人进行干预 6 个月后降低肝脏脂肪含量的功效。

更新日期：2024-07-12

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南